Press Release

Truvian Appoints Renowned Physician-Scientist and Diagnostic Innovator Dr. Michael Mina as Chief Medical and Strategy Officer

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

ThirdLaw Molecular Rebrands as Ladder Bio; Announces $5.5M Seed Financing Led by Medical Excellence Capital and Appoints Eric Heil as Chief Executive Officer

Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson’s Disease

Pleno Inc. Announces First Commercial Agreement with Slopes Bio, Inc.

Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity

GC Therapeutics Advances Cell Programming with Systematic Discovery of Transcription Factor Combinations

PRO-101: study design and interim results from a Phase 1 study to evaluate the safety, tolerability, PK, and PD of prosetin in ALS

Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson’s Disease

Aspen Neuroscience to Present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting